Loading

JSM Sexual Medicine

Androgen Deprivation Therapy: Parallels in the Treatment of Prostate Cancer and Pedophilia

Letter to the Editor | Open Access | Volume 4 | Issue 7

  • 1. Department of Psychiatry, Harvard Medical School, USA
+ Show More - Show Less
Corresponding Authors
Renée Sorrentino, Department of Psychiatry, Harvard Medical School, USA,
CITATION

Sorrentino R (2020) Androgen Deprivation Therapy: Parallels in the Treatment of Prostate Cancer and Pedophilia. JSM Sexual Med 4(7): 1057.

DEAR EDITOR

Chemical castration has been used to treat male pedophiliacs in conjunction with psychotherapy with some success [1-5]. The underlying neuroendocrine mechanism for this treatment is to lower testosterone or it’s efficacy on the higher behavioral centers that drive sexual behaviors [3].The recent discoveries in the chemotherapy of prostate cancer may allow us to be able to utilize these paradigms in treating male pedophiliacs. A review of these agents and their mechanism of action will possibly pave the way for future treatment of pedophiliacs.

There are three possible mechanisms for lowering testosterone and/or its efficacy in the treatment of prostate cancer: surgical castration, agonists or antagonists of testosterone, or receptor blockade of testosterone. These treatments have been referred to as androgen deprivation therapy (ADT). In this paper the parallels between treating prostate cancer and treating male pedophiliacs will be pointed out and hopefully will direct the future use of these agents as ADT for pedophilia.

Surgical castration was the first attempt at ADT and was the only treatment for prostate cancer for years [6]. Leuprolide has been the gold standard for chemically reducing testosterone levels to castration levels. Chemical castration is effectively achieved by Leuprolide for both prostate cancer and male pedophilia [1,5]. Leuprolide has the deleterious effect of an initial rise in testosterone and delayed suppression of testosterone of up to weeks [7]. This initial rise in testosterone could have negative effects on sexual behavior in pedophiliacs by increasing sexual drive. Leuprolide suppresses testosterone by an ultimate decrease in pituitary luteinizing hormone (LH) release via a decrease in hypothalamic gonadotropic-releasing hormone (GnRH). Leuprolide does not fully decrease pituitary follicle stimulating hormone (FSH). The role of lowered FSH in chemical castration is unclear. To date, Leuprolide is a common ADT agent used to treat sexual offenders including pedophiles.

Degarelix is becoming the gold standard for antagonistic treatment for prostate cancer [8]. Degarelix was first theorized to be effective in paraphilias by Sorrentino in 2011 [9] and subsequently proven to be effective by Landgren et al in 2020 [10]. Degarelix antagonizes GnRH at the pituitary level resulting in a prompt decrease in LH and subsequent gonadal testosterone without a surge in testosterone. Degarelix also inhibits pituitary FSH [10].A drawback to Degarelix is that it must be administered subcutaneously. Relugolix is a new oral anti-GnRH that has shown early promise in the treatment of advanced prostate cancer with the added benefit of a reduction in major adverse cardiovascular effects [11]. Relugolix acts similarly to Degarelix at the hypothalamic-pituitary-gonadal axis but has not yet been studied as a chemical castration treatment in pedophiliacs. Oral Relugolix may very well be the next ADT for pedophiliacs given its effectiveness in lowering both LH and FSH and subsequent testosterone, oral administration, and its reduction in cardiovascular morbidity.

Androgen receptor blockade has now been shown to be an effective ADT in the treatment of castration-resistant prostate cancer (CRPC). Many prostate cancers become resistant over time to lowered testosterone levels and progress as CRPC. Much like antibiotic resistant bacteria the prostate cancer cells adapt their receptors to survive in an androgen deprived environment [12]. Consequently, ADT with lowering testosterone over time, usually two to three years, loses its effectiveness in treating prostate cancer and subsequently androgen receptor blockade is added to the chemotherapy regimen. Biclutamide and flutamide, both androgen receptor blockers, have been used with some success to help solve this problem in CRPC [13]. Aplutamide and enzalutamide are newer blockers that show some promise in combating CRPC [14]. These are added to androgen suppression therapy in CRCP.

Drug repurposing is using a drug that has been proven effective for one disease, e.g. prostate cancer, for another, e.g. pedophilia. A common denominator for prostate cancer growth and pedophilic behavior is testosterone. The goal of treatment between prostate cancer and pedophilia is to lower testosterone or it’s efficacy. A prominent side effect of ADT treatment in males is a diminution of sex drive which speaks to the ability of these agents to cross the blood brain barrier [15,16]. Presumably receptors in the brain which modulate sexual behavior can also be down regulated in the same manner that prostate cancer cells can be with ADT. The importance of this is that it is tempting to speculate that the regrowth of prostate cancer cells after two or three years of lowered testosterone efficacy may mimic the recidivism seen in some pedophiliacs after ADT over time. If this is true, and it certainly seems plausible, then addition of androgen receptor blockade may help prevent or reduce this recidivism in pedophiliacs as it does in prostate cancer.

There is very little new research addressing the treatment of pedophilia with chemical castration for a number of socioeconomic and ethical reasons especially in the United States. Drug repurposing might allow psychiatrists to benefit from the burgeoning research that is being carried out in the prevention or reduction of prostate cancer. This has already been shown with Degarelix that successfully has been used to treat prostate cancer [17]and also shown to reduce or delay the sexual behavior of pedophiliacs [10].ADT combined with psychotherapy may well be the future of treating this very difficult group of patients known as pedophiliacs. Treatment of prostate cancers may give physicians who treat pedophiliacs a ray of hope that this treatment may add to our scant armamentarium in treating pedophiliacs in the very near future.

REFERENCES

1. Turner D, Brikem P. Treatment of Paraphilic Disorders in Sexual Offenders or Men with a Risk of Sexual Offending with Luteinizing Hormone- Releasing Hormone Agonists: An Updated Systematic Review. J Sex Med 2018; 15: 77-93.

2. Alessandra Almeida Assumpção, Frederico Duarte Garcia, Heloise Delavenne Garcia, John M W Bradford, Florence Thibaut, et al. Pharmacologic Treatment of Paraphilias. Psychiatr Clin N Am. 2014; 37: 173-181.

3. Florence Thibaut, Flora De La Barra, Harvey Gordon, Paul Cosyns, John M W Bradford, WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WDSBP) guidelines for the biologic treatment of paraphilias. World J Bio Psychiatry 2010; 11: 604-655.

4. Justine M Schober, Phyllis J Kuhn, Paul G Kovacs, James H Earle, Peter M Byrne, Ruth A Fries. Leuprolide Acetate Suppresses Pedophilic Urges and Arousability. Arch Sex Behav. 2005; 34: 691-705.

5. Alessandra Gallo, Jeffrey Abracen, Jan Looman, Elizabeth Jeglic, Robert Dickey. The Use of Leuprolide Acetate in the Management of High Risk Sex Offenders. Sexual Abuse. 2019; 31: 930-951.

6. Huggins C, Hodges CV. Studies on prostatic cancer. 1. The Effect of Castration, of Estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1941; 167: 948-951.

7. William K Oh, Mary Beth Landrum, Elizabeth B Lamont, Barbara J McNeil, Nancy L Keating. Does oral antiandrogen use before luteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?. Urology. 2010; 75: 642-647.

8. Suzuki H, Uemura H, Mizokami A, Narihiko Hayashi, Yasuhide Miyoshi, Satoshi Nagamori, et al. Phase 1 trial of TAK-385 in hormone treatment-naïve Japanese patients with nonmetastatic prostate cancer. Cancer Med. 2019; 8: 5891-5902.

9. Sorrentino R. Degarelix: An antagonistic to GNHR0 Theoretical and treatment considerations in paraphilias. J Sexual Med. 2012; 9: 327- 329.

10. Landgren V, Malki K, Bottai M, Stefan A, Christoffer R. Effect of gonadotropin-releasing hormone antagonist on risk of committing child sex abuse in men with pedophilic disorder. JAMA Psychiatry. 2020; 77: 1-9.

11. Shore ND, Saad F, Cookson MS, Daniel JG, Daniel RS, Ronald T, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020; 382: 2187-2196.

12. Permutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urology. 2007; 9: S3-S8.

13. Iguchi T, Tamada S, Kato M, Sayaka Y, Takeshi Y, Tatsuya N. Enxalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU_ CRPC study). BMC Cancer. 2019; 19: 339.

14. Heidegger U, Brandt MP, Heck M. Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best? Urol Onc. 2020; 38: 129-136.

15. Ngyuen PL, Alibhai SM, Basaria S, Anthony V D’Amico, Philip WK, Nancy LK, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67: 825-836.

16. Fode M, Mosholt K, Nielsen T, et al. Sexual Motivators and Endorsement of Models Describing Sexual Response of Men Undergoing Androgen Deprivation Therapy for Advanced Prostate Cancer. J Sex Med. 2020; 17: 1538-1543.

17. Shore N. Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol. 2013; 5: 11-24.

Sorrentino R (2020) Androgen Deprivation Therapy: Parallels in the Treatment of Prostate Cancer and Pedophilia. JSM Sexual Med 4(7): 1057.

Received : 20 Aug 2020
Accepted : 13 Sep 2020
Published : 15 Sep 2020
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X